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This is the first report of papillary thyroid carcinoma com-
bined with multiple endocrine neoplasia type 1 (MEN1) in 
Korea. MEN1 is a hereditary disease comprising neoplastic 
disorders such as pituitary, parathyroid and pancreatic neu-
roendocrine tumor, such as gastrinoma. But papillary thyroid 
cancer was never regarded as its component before in Korea. 
Herein we present a 39-year-old woman who manifested 
typical features of MEN1 with a coincidental papillary thyroid 
carcinoma. Although the family history of MEN1 was definite, 
her genetic analysis of DNA had revealed no germline muta-
tion in MEN1 gene locus. Unidentified culprit gene unable us 
further genetic study to find LOH (loss of heterogeneity) in 
11q13, the possible explanation of papillary thyroid carcinoma 
as a new component of MEN1. As we have first experienced 
a case of MEN1 combined with papillary thyroid carcinoma 
in Korea, we report it with the review of literature.
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INTRODUCTION
In 1903, Erdheim first reported concomitant 
parathyroid hyperplasia with pituitary adenoma 
and since 1954 when Wermer reported a family 
with multiple glandular disease, many attentions 
have been paid on the hereditary characteristics of 
the disease. The multiple endocrine neoplasia type 
1 (MEN1) is a disease that is transmitted in an 
autosomal dominant way with the incidence of 
0.2- 2 in 100,000 persons, without sexual pre-
ference.
1 The disease is made by the germline 
mutation of a tumor suppressor gene on chromo-
some 11 long arm 13 (11q13), which encodes 
menin protein, a transcriptional protein.
2 MEN1 is 
characterized by coincidental, multiple endocrine 
tumors such as parathyroid, anterior pituitary and 
pancreatic islet cell tumor and less frequently, 
anterior thymoma, pheochromocytoma, cutaneous 
lipoma, facial fibroangioma, esophageal leio-
myoma, thyroid adenoma may also occur.
1-3 
Speaking of the thyroid disease, it can be 
observed in over 25% of MEN1 patients,
3,4 and it 
can be detected incidentally during parathyroid 
surgery in MEN1 patients. But so far, only two 
cases of thyroid carcinoma combined with MEN1 
were reported, and they confirmed that papillary 
thyroid cancer did not correlate to MEN1.
4,5
Our report which is the first case in Korea, with 
the following 2 cases above, is anticipated to pro-
vide the important information for the characteri-
zation of the developmental association of these 
two diseases.
CASE REPORT
A 39-year-old woman visited the hospital for 
evaluation of MEN1, as she had her two older 
brothers diagnosed of the disease one year before. 
The patient had no past history such as diabetes, 
hepatitis, hypertension, pulmonary tuberculosis 
and others. She had two children and normal 
menstrual cycle, but in recent two years, the cycle 
became irregular. She presented no particular Hai-Jin Kim, et al. 504
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Fig. 2. Sellar MRI shows 0.9 × 0.6 mm sized microade-
noma in left portion of pituitary gland.
Fig. 5. Histologic feature of thyroid papillary carcinoma 
showing inclusion body (H&E stain, × 100).
Fig. 1. Thyroid US shows about 1.5 cm irregular mass at 
upper pole of right thyroid gland.
Fig. 4. Histologic feature of parathyroid hyperplasia (H&E
stain, × 100).
Fig. 3. Abdominal dynamic CT shows 0.68 cm sized arte-
rial enhancing mass at pancreatic body.
symptoms except that on physical examination, a 
1.5 cm sized nodule in her right thyroid lobe was 
palpated. Laboratory tests revealed no abnormal 
results except for increased PTH (201 ng/L, nor-
mal value: 13 - 104 ng/L), calcium (2.77 nmol/L), 
prolactin (149 ug/L, normal value: 3.8 - 31.4 ug/L), 
and gastrin (555 ng/L, normal value: 0 - 90 ng/L) 
levels. On cervical ultrasonography, a 1.5 cm sized 
low density nodule was found on right posterior 
lobe of the thyroid (Fig. 1) and on sellar MRI, a 
0.9 × 0.6 cm sized pituitary mass was seen on the 
left sellar wing (Fig. 2). Furthermore on abdomi-
nal computed tomography (CT) scan, we found a 
0.68 cm sized contrast-enhanced mass on pan-
creatic body portion (Fig. 3). Based on these 
results, we could conclude that she had hyper-
parathyroidism, gastrinoma and prolactinoma 
with thyroid tumor. She underwent parathy-
roidectomy, thyroidectomy and the pathologic 
results revealed bilateral parathyroid hyperplasia 
(Fig. 4) and a typical thyroid papillary cancer 
(T2N0M0) (Fig. 5). For the treatment of pro-Relationship of MEN Type 1 and Papillary Cancer 505
Yonsei Med J Vol. 49, No. 3, 2008
lactinoma and gastrinoma, she is now taking 
bromocriptin and proton-pump inhibitor daily. In 
the analysis of all coding exons of MEN1 of the 
patient, a silent mutation was detected in the exon 
9 and polymorphism in the exon 10, however 
these results suggest no specific abnormality in 
MEN1 disease, reports from the Korean Heredi-
tary Tumor Registration Center.
DISCUSSION
MEN1 is a familial disease that presents para-
thyroid, pituitary and pancreatic islet cell tumor 
or hyperplasia. So far, 16 cases have been reported 
in Korea, and among them, the family history 
were confirmed in 5 cases.
6 Our case is the first 
report of thyroid papillary cancer combined with 
MEN1 in Korea, and the third case report world-
wide.
4,5
In the year of 1988, using the method of linkage 
analysis of polymorphic DNA sequencing,
7 MEN1 
gene was detected in chromosome 11q13
8 and 
subsequently loss of heterogeneity in MEN1 gene 
was found.
9 MEN1 gene is a tumor suppressor 
gene that encodes the nuclear protein, menin, 
which regulates cell growth and cycle and when 
this protein deficit occurs, MEN1 develops. 
Tumors involved endocrine glands in MEN1 
patients demonstrate loss of heterogeneity (LOH) 
at the locus of the MEN1 tumor suppressor gene. 
Menin, the protein encoded by Menin gene is 
ubiquitously expressed in endocrine tissues, and 
less commonly these patients can present with 
tumors of other endocrine glands including 
thyroid. To verify whether papillary thyroid can-
cer is developed as a part of MEN1 disease, one 
should prove that allelic LOH of 11q13 in thyroid 
tissue be identical to that of leukocyte DNA.
3,4  But 
as in our case, the lack of obvious LOH of the 
MEN1 locus in the papillary carcinoma suggests 
that deletion of the MEN1 tumor suppression 
might not be etiologically related to the onco-
genesis of the papillary thyroid carcinoma. 
Furthermore papillary thyroid carcinoma was 
found only in our patient and not in any of the 
family members involved MEN1. So the pos-
sibility that thyroid carcinoma is etiologically 
associated with MEN1 seems to be low.
In the analysis of MEN1 genetic study, about 
20% may have false negative results due to the 
diversity of the causative mutation and scattered 
position in the entire open reading frame. More-
over approximately 10% new germline mutations 
are being detected in the overall MEN1 patients, 
which is the reason why the association of 
genotype and phenotype could not be identical in 
10 - 30% of patients. Similarly, in our case, we 
could not find the causative mutation in the 
patient and family.
In Korea, among five MEN1 families, only four 
family germline mutations were found which are 
in concordance with other reports with 80% 
positive detection rate.
6 Among mutations dis-
covered in Korea, three were new ones and the 
remaining one has already been revealed before.
6 
In the other hand, thyroid carcinoma has been 
reported in the range of 1.7% to 6% of patients 
with primary hyperparathyroidism.
10-12  Hypotheses 
have been presented to address these findings, but 
no firm conclusions exist at this time regarding 
the etiology of synchronous thyroid and para-
thyroid disease.
13-15  Only one factor like prior 
exposure to radiation may play a role in the 
association. But in our case, the patient had no 
past history of radiation exposure. So there seems 
to be little correlation between the two diseases in 
our case.
16
Our case suggests three possibilities of the 
development of thyroid papillary cancer as a 
component of MEN1. First possibility is the close 
association between the two genes. But no data 
exists supporting this hypothesis yet. Second, the 
possibility of the incidental occurrence of thyroid 
papillary cancer for it occurs with a high pre-
valence. Presently, the opinion that these two 
diseases' occurrence is separate is prevalent. 
However, there exit two reports which have 
evidence for their intimate correlation. Finally, the 
possibility that it is a new type of familial disease 
causing two diseases by a genetic abnormality 
that is not characterized yet. 
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